Internal Medicine, Infectious Disease · Dayton, OH
NPI
1407848252
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
33 W Rahn Rd
Dayton, OH, 45429
Phone (937) 433-8990
Groups this clinician bills Medicare through
Medicare paid, 2024
$67K
886 services
Medicare patients, 2024
235
Average age 72
Drug cost, 2024
$762K
654 prescriptions
Company payments, 2024
$150
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James H Galbraith was code 99232 (hospital e&m - subsequent), 546 times for 173 patients. In total James H Galbraith billed 886 services in 15 codes, and Medicare paid $67K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-12-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 546 | 173 | $59.29 | $32K |
| 99223 Hospital E&M - Initial | Facility | 153 | 139 | $130.96 | $20K |
| 99233 Hospital E&M - Subsequent | Facility | 100 | 63 | $89.71 | $8,971 |
| 99213 Office E&M - Established | Office | 49 | 34 | $57.12 | $2,799 |
| 99214 Office E&M - Established | Office | 21 | 19 | $91.49 | $1,921 |
By year: 2022 $64K for 845 services; 2023 $65K for 851 services; 2024 $67K for 886 services.
Medicare prescription drug claims, 2024
In 2024, the drug James H Galbraith prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 60 prescriptions and refills. In total James H Galbraith wrote 654 Medicare prescriptions that cost $762K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 60 | 60 | Under 11 | $227K |
| Ceftriaxone Ceftriaxone Sodium | 51 | 51 | 11 | $8,873 |
| Cefadroxil Generic | 42 | 72 | 14 | $2,098 |
| Juluca Dolutegravir/Rilpivirine | 41 | 41 | Under 11 | $148K |
| Daptomycin Generic | 39 | 39 | Under 11 | $8,345 |
| Cefazolin Sodium Generic | 35 | 35 | Under 11 | $3,246 |
| Doxycycline Hyclate Generic | 29 | 55 | Under 11 | $639 |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 27 | 27 | Under 11 | $6,609 |
| Stribild Elviteg/Cob/Emtri/Tenofo Disop | 24 | 24 | Under 11 | $93K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 22 | 39 | Under 11 | $537 |
| Ertapenem Ertapenem Sodium | 20 | 20 | Under 11 | $12K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 18 | 18 | Under 11 | $73K |
| Amoxicillin Generic | 17 | 23 | Under 11 | $143 |
| Lamivudine Generic | 14 | 14 | Under 11 | $404 |
| Vancomycin Hcl Generic | 14 | 14 | Under 11 | $1,769 |
Brand drugs: 229 claims; generic drugs: 425 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid James H Galbraith $150 ($150 in general payments such as food, travel and fees) from 1 company. The largest payer was Smith+Nephew, Inc. with $150.
| Company | Payments | Amount |
|---|---|---|
| Smith+Nephew, Inc. SNN | 1 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.